Certara (NASDAQ:CERT) Shares Gap Up on Analyst Upgrade

Certara, Inc. (NASDAQ:CERT)’s share price gapped up before the market opened on Tuesday after Leerink Partners upgraded the stock from a market perform rating to an outperform rating. The stock had previously closed at $9.04, but opened at $9.43. Leerink Partners now has a $13.00 price target on the stock. Certara shares last traded at $9.5850, with a volume of 298,535 shares.

Other analysts have also recently issued research reports about the company. Redburn Partners set a $10.00 price objective on Certara in a research report on Friday, November 21st. Morgan Stanley decreased their price target on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. BMO Capital Markets assumed coverage on shares of Certara in a research report on Thursday, November 13th. They issued a “market perform” rating and a $9.00 price objective for the company. Craig Hallum initiated coverage on shares of Certara in a research note on Monday, September 29th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Rothschild & Co Redburn initiated coverage on shares of Certara in a research note on Friday, November 21st. They issued a “buy” rating and a $10.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $12.92.

Hedge Funds Weigh In On Certara

Hedge funds have recently made changes to their positions in the stock. Kopion Asset Management LLC increased its holdings in shares of Certara by 49.9% during the 4th quarter. Kopion Asset Management LLC now owns 982,710 shares of the company’s stock worth $8,658,000 after buying an additional 327,064 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new stake in Certara during the third quarter valued at about $2,844,000. Morningstar Investment Management LLC acquired a new stake in Certara during the third quarter worth about $1,598,000. Wasatch Advisors LP increased its stake in Certara by 28.6% during the third quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock worth $212,608,000 after acquiring an additional 3,865,455 shares during the last quarter. Finally, Parkman Healthcare Partners LLC raised its holdings in shares of Certara by 10.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 551,850 shares of the company’s stock worth $6,744,000 after purchasing an additional 51,850 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Up 5.9%

The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of 138.04 and a beta of 1.46. The firm has a 50 day moving average price of $9.28 and a two-hundred day moving average price of $10.59.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. The firm had revenue of $104.62 million for the quarter, compared to analyst estimates of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. During the same quarter last year, the firm posted $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, equities analysts expect that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.